<DOC>
	<DOCNO>NCT00143065</DOCNO>
	<brief_summary>This purpose study assess toxicity rate complete overall response use fludarabine , rituximab , alemtuzumab treat patient B-chronic lymphocytic leukemia small lymphocytic leukemia receive previous treatment .</brief_summary>
	<brief_title>Fludarabine , Rituximab , Alemtuzumab B-Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>Immunotherapy , treatments work boost immune function body , monoclonal antibody show efficacy different type leukemia . Researchers learn manufacture antibody outside human body bind specific target cancer cell . Monoclonal antibody design recognize different protein specific cancer cell . The current study combine two monoclonal antibody , rituximab fludarabine . Rituximab attach protein call CD20 antigen find almost exclusively surface B-cells leukemia . Once rituximab attache protein , immune system activates kill malignant B-cells . Alemtuzumab work similar way attach CD25 antigen also activity patient p53 gene mutation . Previous study indicate rituximab alemtuzumab separately efficacy lymphocytic leukemia . Research also show fludarabine work disease . Rituximab fludarabine combination appear high response rate patient . Researchers seek improve efficacy data add alemtuzumab combination rituximab fludarabine study . This study evaluate safety efficacy fludarabine , rituximab , alemtuzumab patient previously treat B-cell lymphocytic leukemia small lymphocytic leukemia . Blood bone marrow test assess genetic feature associate response therapy , immune recovery , mechanisms alemtuzumab 's signaling , rout drug resistance , trace residual disease follow complete response patient . Patients study receive fludarabine , rituximab , alemtuzumab . These drug administer intravenous infusion . The treatment period last 22 week . Fludarabine give week one , 5 day week 2 , 5 day week 6 , 10 , 14 , 18 , 22 . Rituximab give week one , 3 time second week , day one week 6 , 10 , 14 , 18 , 22 . Alemtuzumab give 3 time week one , week 2 , day 2 week 6 , 10 , 14 , 18 , 22 . The dosage amount rituximab alemtuzumab increase depend upon degree side effect . Several test exams give throughout study closely monitor patient . Treatments discontinue due disease growth unacceptable side effect .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Must BCLL/SLL active disease &gt; =1 prior systemic therapy ECOG PS 02 . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antigens , CD5</keyword>
	<keyword>Antigens , CD19</keyword>
	<keyword>Antigens , CD20</keyword>
</DOC>